Bristol-Myers Squibb and ZymoGenetics have released final results from phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naive hepatitis C virus (HCV) patients.
Quintiles has entered into a strategic alliance with Eisai, to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts
Bristol-Myers Squibb has reported 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis. According to the data Baraclude demonstrated greater viral suppression
Gilead Sciences has presented its three-year open label data from two pivotal phase III clinical trials, studies 102 and 103, evaluating the safety and efficacy of once-daily Viread
Eli Lilly and Company (Lilly) has opened a new biotechnology center on the West Coast to discover and develop more biotechnology medicines. The Lilly Biotechnology Center – San
GlaxoSmithKline Pharmaceuticals (GSK) has reported its financial results for the third quarter ended September 2009. The company has reported 12% increase in net sales as compared to the
AcelRx Pharmaceuticals (AcelRx) has completed an end-of-phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company’s proprietary NanoTab dosage form, which enables
ExonHit has presented clinical data on the validation set ‘Alzheimer patients versus healthy controls’ for AclarusDx, its blood-based diagnostic test for the detection of Alzheimer’s disease (AD). This
Sunesis Pharmaceuticals (Sunesis) has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial. Its a phase 2 dose regimen optimisation trial of single agent voreloxin
China Medicine has reported that through its wholly-owned subsidiary, Konzern, it has signed an equity transfer agreement to acquire 100% of equity interests in Sinoform. Under the terms
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.